louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05207969: Efficacy of the Act of Urination to Relief the Pain During Flexible Cystoscopy Procedure.
Official title: Efficacy of the Act of Urination to Relief the Pain During Flexible Cystoscopy Procedure.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Hematuria
Bladder Ca
Bladder Stone
Urologic Diseases
Lead sponsor: Universiti Sains Malaysia
Sponsor class: OTHER
First posted: 2022-01-26
Enrollment: 58
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This research is about modification during routine cystoscopy (scope in the bladder) procedure \[ experimental research \]. The goal of the study is to evaluate patient experience with cystoscopy by using procedural modification to reduce pain perception. The investigator aim for quality improvement of the current methods of cystoscopy to achieve a better patient experience.

Detailed description: Study Area

-Department of Urology, Hospital Universiti Sains Malaysia.

Study population. -Patient who is required for flexible cystoscopy procedure attending Urology Unit in Hospital USM

Participants

Inclusion Criteria :

• Adult (\>18 years old)

Exclusion criteria:

* Analgesic use within 24hours
* History of stricture ,urinary tract infection, existing urethral pain
* Secondary procedure(example stent, stone removal, fulguration)

Withdrawal Criteria

* Change of mind
* Found to be outside the parameters of inclusion criteria, and inside the parameters of exclusion criteria
* Breach of Protocol

Eligibility criteria: Inclusion Criteria:

* age more 18 years old

Exclusion Criteria:

* Analgesic use within 24hours
* History of stricture ,urinary tract infection, existing urethral pain
* Secondary procedure(exp stent, stone removal, fulguration)

Primary outcomes:
measure: 1)To determine the efficacy of the act of urination in reducing patient urethral pain during flexible cystoscopy procedure.
timeFrame: During cystoscopy procedure
Secondary outcomes:
measure: 2)To determine the association between the act of urination with relaxation of external urethral sphincter during flexible cystoscopy procedure.
timeFrame: During cystoscopy procedure
Other outcomes:
Locations:
city: Kota Bharu
country: Malaysia
facility: Hospital University Sains Malaysia
state: Kelantan
Study officials:
affiliation: HUSM
name: MUNAWWAR BIN ADNAN DR, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02253069: PHMB-based Antiseptic Use in Full-thickness Surgical Wounds
Official title: A Study of Polyhexanide-based Antiseptic in Full-thickness Surgical Wounds in Dermatologic Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Surgical Site Infections
Lead sponsor: Region Skane
Sponsor class: OTHER
Collaborators: name: Vinnova
First posted: 2014-10-01
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: To study the effect of applying a PHMB-based antiseptic solution to tie-over dressings in full-thickness surgical wounds in dermatologic surgery in order to minimise the development of surgical site infections. The bacterial dynamics in wounds pre-,intra-, and postoperatively will be examined in order to understand the pathogenesis of surgical site infections better.

Detailed description: 40 patients with suspected skin cancer in the face planned for full-thickness surgery will be randomised into two groups: One will receive a traditional tie-over dressing saturated with NaCl and the other group will receive a tie-over dressing saturated with a PHMB-based antiseptic. A quantitative and qualitative bacterial analysis of wounds by using a modified Levine's swabbing technique will be carried out pre-,intra-,and postoperatively. The effect of nasal colonisation with S.aureus on the development of surgical site infections will be investigated. All wounds will be followed a week after surgery to assess development of infections.

Eligibility criteria: Inclusion Criteria:

* Patients planned for full-thickness skin grafting in the face

Exclusion Criteria:

* Patients with no diabetes
* Patients with no current/previous/recent antibiotic therapy

Primary outcomes:
measure: Measuring colony forming units in swabs collected from wounds pre-,intra- and postoperatively (7 days after surgery1). Change in bacterial load will be attributed to the effect of applying an antiseptic solution to wound dressings.
timeFrame: 7 days
Secondary outcomes:
Other outcomes:
Locations:
city: Lund
country: Sweden
facility: Department of dermatology, Skåne university hospital
Study officials:
affiliation: Department of Dermatology, Skåne University Hospital, Lund
name: Karim Saleh, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Saleh K, Sonesson A, Persson B, Riesbeck K, Schmidtchen A. A descriptive study of bacterial load of full-thickness surgical wounds in dermatologic surgery. Dermatol Surg. 2011 Jul;37(7):1014-22. doi: 10.1111/j.1524-4725.2011.02040.x. Epub 2011 May 25.
Clinical trial NCT05904769: A Study of Non-invasive Measurement of Blood Glucose and Blood Pressure
Official title: Non-invasive Measurement of Blood Glucose, Blood Pressure and Extrapolation of QRS Complex Using a Wrist Wearable Photoplethysmography Sensor
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Diabetes
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2023-06-15
Enrollment: 87
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The purpose of this research is to compare blood glucose, blood pressure and electrocardiogram (ECG) readings on the LIFELEAF Smartwatch compared to standard methods of measurement.


Eligibility criteria: Inclusion Criteria:

* Diabetic patients on insulin undergoing four times daily blood sugar checks as part of standard of care.
* Patients undergoing continuous monitoring for heart rate and blood pressure as part of their routine care.
* Patients undergoing catheter ablation for atrial fibrillation.

Exclusion Criteria:

* Patients unable to provide informed consent.
* Patients without arms as these are needed to wear the wrist-based sensor.

Primary outcomes:
measure: Systolic blood pressure
timeFrame: Baseline
measure: Diastolic blood pressure
timeFrame: Baseline
measure: Blood glucose level
timeFrame: Baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic Minnesota
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: Narayan Guru G. Kowlgi, MBBS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00747669: Pharmacokinetic Study of Synera™ in Neonates and Infants
Official title: A Pharmacokinetic Study of Synera™ (Lidocaine 70 mg and Tetracaine 70 mg Topical Patch) to Evaluate the Systemic Exposure to Lidocaine and Tetracaine in Neonates and Infants
Study type: INTERVENTIONAL
Overall status: SUSPENDED
Phase: PHASE4
Conditions: Pain
Lead sponsor: ZARS Pharma Inc.
Sponsor class: INDUSTRY
First posted: 2008-09-05
Enrollment: 11
Sex: ALL
Maximum age (years): 4
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: This study will measure the amount of lidocaine and tetracaine in the blood after a 30 minute application of Synera.


Eligibility criteria: Inclusion Criteria:

* Subject must be an infant of 1 to 4 months of age and weigh at least 2.5 kg or a neonate of 0 to 4 weeks postnatal age with a gestation period of at least 37 weeks, and weigh at least 1.8 kg.
* Subject is scheduled to have a medically indicated minor superficial procedure for which topical local anesthesia would provide a benefit.
* Subject has or will have an indwelling vascular access catheter for blood sampling at the time of the procedure visit. The indwelling vascular access catheter placement must be necessary for medical reasons other than the purposes of this study.
* The additional blood draws for the purposes of this study do not pose more than a minor risk to the health and welfare of the subject.

Exclusion Criteria:

* Subject has known allergies or sensitivities to any component of Synera.
* Subject has clinically significant laboratory abnormalities.
* Subject has known multiple allergies that could indicate hypersensitive skin.
* Subject has known active atopic dermatitis at or near the patch application site.

Primary outcomes:
measure: Evaluate the systemic exposure to lidocaine and tetracaine following application of Synera
timeFrame: 30 hours
Secondary outcomes:
measure: Monitor the nature and frequency of adverse events
timeFrame: 30 Hours
Other outcomes:
Locations:
city: Washington
country: United States
facility: Children's National Medical Center
state: District of Columbia
Study officials:
affiliation: ZARS Pharma
name: ZARS Clinical Development
role: STUDY_CHAIR
References:
Clinical trial NCT00920569: Recirculation, Oxygenator Blood Volume and Cardiac Output Measurements During Extracorporeal Membrane Oxygenation
Official title: Measurement of Recirculation, Oxygenator Blood Volume and Cardiac Output in ECMO Using a Modified Transonic Systems (tm) HD02 Monitoring System
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Recirculation
Oxygenator Blood Volume
Cardiac Output
Venoarterial Extracorporeal Membrane Oxygenation
Venovenous Extracorporeal Membrane Oxygenation
Keywords: cardiac output
recirculation
oxygenator blood volume
venoarterial extracorporeal membrane oxygenation
venovenous extracorporeal membrane oxygenation
Lead sponsor: Transonic Systems Inc.
Sponsor class: INDUSTRY
Collaborators: name: National Heart, Lung, and Blood Institute (NHLBI)
First posted: 2009-06-15
Enrollment: 8
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Measurement of cardiac output in venoarterial extracorporeal membrane oxygenation patients, recirculation in venovenous extracorporeal membrane oxygenation patients and oxygenator blood volume in venoarterial and venovenous extracorporeal membrane oxygenation patients.

Brief summary: This study is to test the usefulness of ultrasound dilution measurements in patients on extracorporeal membrane oxygenation. Measurements may include; efficiency of support (recirculation), amount of clotting in the oxygenator (oxygenator blood volume), and how well the heart is working (cardiac output). At the present time there are no devices available to perform these functions.

Detailed description: At the present time there are no devices available to measure recirculation, oxygenator blood volume and cardiac output in patients on extracorporeal membrane oxygenation. The study uses an external monitor, laptop computer, clamp on flowsensors and ultrasound dilution technology to measure blood flow. Measurements are made by injecting 0.5 - 1 ml/kg of sterile isotonic saline into the patient's extracorporeal circuit. The subject will be monitored throughout the measurements. The measurements will be coordinated with the regular care of the extracorporeal circuit.

Eligibility criteria: Inclusion Criteria:

* Neonatal, pediatric or adult patients receiving venoarterial or venovenous extracorporeal membrane oxygenation.

Exclusion Criteria:

* Patients not receiving venoarterial or venovenous extracorporeal membrane oxygenation.

Primary outcomes:
measure: Cardiac output, recirculation or oxygenator blood volume measurements made in patients receiving extracorporeal membrane oxygenation.
timeFrame: Duration of extracorporeal membrane oxygenation
Secondary outcomes:
Other outcomes:
Locations:
city: Ann Arbor
country: United States
facility: University of Michigan, Medical School
state: Michigan
Study officials:
affiliation: University of Michigan
name: Jonathan Haft, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Transonic Systems Inc.
name: Nikolai M Krivitski, PhD, DSc
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03975569: Study of the Vaginal Microbiota and the Potential of a Vaginal Probiotic Cream in Vaginal Candidosis
Official title: Studie Van de Vaginale Microbiota en Het Potentieel Van Een Vaginale Zalf Met Probiotica Bij Vaginale Candidose
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Candidiasis, Vulvovaginal
Keywords: vaginal, yeast infection, candida, candidosis
Lead sponsor: University Hospital, Antwerp
Sponsor class: OTHER
First posted: 2019-06-05
Enrollment: 20
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study evaluated the effect of a vaginal gel containing three live probiotic bacteria on vaginal Candida albicans infection in flemish patients (n=20). The therapeutic effects of the gel will be clinically evaluated (vaginal pH, microscopic and clinical scores). The effect on the vaginal microbiome will be evaluated through 16S ribosomal RNA amplicon sequencing via MiSeq Illumina and polymerase chain reaction (PCR) for Candida albicans.


Eligibility criteria: Inclusion Criteria:

* Informed consent
* willing to adhere to protocol
* premenopausal
* positive Candida microscopy and/or culture
* at least two of the following vaginal symptoms: burning, itching, redness, fissure, discharge, vulvar edema, postcoital itching, lesions with partner

Exclusion Criteria:

* vaginal use of any products 1 week or less before randomization
* use of oral or local antimycotic treatment 1 week or less before randomization
* unprotected sexual contact 24 hours preceding randomization
* vaginal douching 24 hours preceding randomization
* patient does not agree to participate in the study

Primary outcomes:
measure: Vaginal persistence of Candida species
timeFrame: through study completion, estimated 1 year
Secondary outcomes:
measure: Clinical scores of patients
timeFrame: through study completion, estimated 1 year
measure: Microbiome analysis
timeFrame: through study completion, estimated 1 year
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00755469: Post-conditioning to Reduce Infarct Size
Official title: Modification of Reperfusion by "Post-Conditioning" Reduces Infarct Size in Acute Myocardial Infarction
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Myocardial Infarction
Keywords: Reperfusion injury
Post-Conditioning
Infarct size
Lead sponsor: Minneapolis Heart Institute Foundation
Sponsor class: OTHER
Collaborators: name: Society for Cardiovascular Angiography and Interventions
First posted: 2008-09-19
Enrollment: 43
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: When angioplasty (PTCA) and stenting of the blood vessels of the heart is the treatment for a Heart Attack, there is damage to the heart muscle that is caused by the sudden opening of the blood vessels. This is called "reperfusion injury". The cell death is due to inflammation and the generation of free radicals.

The primary objective of this study is to determine if post-conditioning(four brief (30 second) PTCA balloon inflations) reduces damage to the heart muscle. This will be measured by heart enzyme tests-CK measurements- and by cardiac MRI.


Eligibility criteria: Inclusion Criteria:

* Age ≥ 18 \< 80
* Able to give informed consent
* 100% occlusion of a major epicardial vessel with TIMI 0 Flow

Exclusion Criteria:

* Significant collateral blood flow to the distal vasculature of the occluded vessel.
* Previous CABG
* Previous q-wave myocardial infarction in the same territory

Primary outcomes:
measure: Infarct size, determined by late-enhancement measurements of the LV using gadolinium contrast with cardiac MRI
timeFrame: 3 months
Secondary outcomes:
measure: The degree of Microvascular Obstruction (MVO), as measured by Cardiac MRI
timeFrame: 3 months
Other outcomes:
Locations:
city: Minneapolis
country: United States
facility: Abbott Northwestern Hospital
state: Minnesota
Study officials:
affiliation: Minneapolis Heart Institute at Abbott Northwestern Hospital
name: Jay H Traverse, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Traverse JH, Wang YL, Chavez, IJ, Lesser JR, Pedersen WR, Mirheydar H, Henry TD. Post Conditioning reduces infarct size and improves LV function during acute myocardial infarction. Circulation 2006;114:II-344.
citation: Staat P, Rioufol G, Piot C, Cottin Y, Cung TT, L'Huillier I, Aupetit JF, Bonnefoy E, Finet G, Andre-Fouet X, Ovize M. Postconditioning the human heart. Circulation. 2005 Oct 4;112(14):2143-8. doi: 10.1161/CIRCULATIONAHA.105.558122. Epub 2005 Sep 26.
citation: Garcia S, Henry TD, Wang YL, Chavez IJ, Pedersen WR, Lesser JR, Shroff GR, Moore L, Traverse JH. Long-term follow-up of patients undergoing postconditioning during ST-elevation myocardial infarction. J Cardiovasc Transl Res. 2011 Feb;4(1):92-8. doi: 10.1007/s12265-010-9252-0. Epub 2010 Dec 7.
Clinical trial NCT05544669: Calcium-phosphate Complications Induced by IV Iron Supplementation in Patients With Rendu-Osler Disease
Official title: Study of Calcium-phosphate Complications Induced by the Administration of IV Iron Supplementation in Patients With Rendu-Osler Disease
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Rendu Osler Disease
Keywords: Rendu-Osler disease
Hypophosphatemia
Injectable iron
Osteomalacia
Carbohydrates
Iron deficiency
Lead sponsor: University Hospital, Strasbourg, France
Sponsor class: OTHER
First posted: 2022-09-16
Enrollment: 220
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Major subject (≥ 18 years old) suffering from Rendu-Osler disease and receiving IV iron supplementation

Brief summary: Hypophosphatemia induced by treatments with injectable iron is a frequent side effect already reported during marketing. Situations of osteomalacia secondary to these hypophosphatemias are rarer and reported in the form of case reports in the literature. Hypophosphatemia in this context is attributed to an excess of FGF-23 (defect of degradation linked to carbohydrates in martial preparations) with renal leakage of phosphate.

Rendu-Osler disease (ROM) is an autosomal dominant genetic disease, favoring the formation of vascular malformations, including nasal and digestive telangiectasias causing repeated bleeding, even hemorrhages. Iron deficiency is frequent and profound there, and oral martial treatments are often insufficient to compensate for these losses. Regular iron infusions, to avoid transfusions, are often necessary.


Eligibility criteria: Inclusion criteria:

* Major subject (≥ 18 years old)
* suffering from Rendu-Osler disease and receiving IV iron supplementation
* Subject not objecting, after information, to the reuse of their data for scientific research purposes

Exclusion criteria:

* Subject who expressed their opposition to participating in the study
* Subject under safeguard of justice
* Subject under guardianship or curatorship

Primary outcomes:
measure: Occurrence of a bone crack and/or fracture
timeFrame: Files analysed retrospectively from January 01, 2018 to December 31, 2022 will be examined
Secondary outcomes:
Other outcomes:
Locations:
city: Strasbourg
country: France
facility: Service de Médecine interne - CHU de Strasbourg - France
Study officials:
References:
Clinical trial NCT02149069: Blood Management Program in the Post - Operative Period.
Official title: Blood Management Program: Appropriateness of Transfusion Therapy in the Post - Operative Period.
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Excessive Amount of Blood / Fluid Transfusion
Lead sponsor: Azienda USL Reggio Emilia - IRCCS
Sponsor class: OTHER_GOV
First posted: 2014-05-29
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: patients undergoing complex surgical procedures

Brief summary: A care path in the field of transfusion medicine was creates at ASMN - IRCCS addressed to patients undergoing complex surgical procedures.

Detailed description: This pathway is called Blood Management Program (BMP).

The implementation of this process should improve transfusion therapy in the peri-operative period in order to:

* correct the transfusional approach to surgical patients
* optimize the management of transfusional resources (red blood cells, plasma, platelets)
* optimize the management of plasma derivatives, drugs and techniques designed to limit the use of homologous blood

Eligibility criteria: Inclusion Criteria:

-All patients undergoing complex surgical procedures

Exclusion Criteria:

Primary outcomes:
measure: Evaluation of therapeutic appropriateness for Red Cells - Plasma - Platelets transfusion: comparison between prospective vs. retrospective data in ASMN ,Reggio Emilia (Italy)
timeFrame: 24 months
Secondary outcomes:
Other outcomes:
Locations:
city: Reggio Emilia
country: Italy
facility: IRCCS-Arcispedale Santa Maria Nuova
state: Emilia Romagna
Study officials:
affiliation: ASMN-IRCCS
name: Erminia Di Bartolomeo, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04514068: Effect of Electroacupuncture on P6 Acupoint on Hypertensive Patients.
Official title: Effect of Electroacupuncture on P6 Acupoint on Hypertensive Patients.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Hypertension
Keywords: acupuncture
Lead sponsor: Ong Fujian Chinese Physician Hall
Sponsor class: OTHER
First posted: 2020-08-14
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a randomized controlled clinical trial with three parallel arms. This trial aims to evaluate the effectiveness of electroacupuncture on P6 acupoint for patients with hypertension,with respect to decreasing their blood pressure, safety of acupuncture ,and improving their quality of life as well.


Eligibility criteria: Inclusion Criteria:

* Patients above 18 years old
* Have not recently had any changes in anti-hypertensive medications
* Have not recently been discharged from hospital/are stable
* Is not having any acute infection.

Exclusion Criteria:

* Trypanophobia
* Below 18 years of age
* Is currently having an acute infection
* Is unstable or have been discharged recently from hospital
* Changes made to anti-hypertensive medications

Primary outcomes:
measure: Reduction of blood pressure.
timeFrame: up to 6 months
measure: Reduction of Heart Rate
timeFrame: up to 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Singapore
country: Singapore
facility: Ong Fujian Chinese Physician Hall
Study officials:
affiliation: Ong Fujian Chinese Physician Hall
name: Lin Ho Wong, MB BCH BAO
role: STUDY_DIRECTOR
affiliation: Ong Fujian Chinese Physician Hall
name: Pang Ong Wong, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Ong Fujian Chinese Physician Hall
name: Eng Soon Ong, Bachelor of TCM
role: STUDY_CHAIR
affiliation: Ong Fujian Chinese Physician Hall
name: Choo Keok Lim, PhD
role: STUDY_CHAIR
References: